Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Life Sciences Fortuitous Opportunity: NASA's Twins Study

This article was originally published in Scrip

Executive Summary

While the goal of the yearlong mission aboard the International Space Station (ISS) involving US astronaut Scott Kelly and his Russian counterpart cosmonaut Mikhail Kornienko, who both returned to Earth on March 2, was intended to examine the effects of microgravity on the human body with the aim of reducing the health risks on future crewmembers, NASA serendipitously fell into a fortuitous situation to study spaceflight at the molecular level, potentially providing the life sciences sector a wealth of data – an opportunity that may not come around again for quite some time, if at all.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC064696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel